Literature DB >> 15206996

Acute and clinically relevant drug-induced liver injury: a population based case-control study.

Francisco J de Abajo1, Dolores Montero, Mariano Madurga, Luis A García Rodríguez.   

Abstract

AIMS: To provide quantitative information about the absolute and relative risks of acute and clinically relevant drug-induced liver injury.
METHODS: We performed a population-based case-control study using the UK-based General Practice Research Database as the source of information. A total of 1,636,792 persons subjects aged 5-75 years old registered in the database from 1 January, 1994 to 31 December, 1999 were followed-up for a total of 5,404,705 person-years. Cases were identified by an exhaustive computer search, then reviewed manually and finally validated against the clinical records. Only idiopathic cases serious enough to be referred to hospital or a consultant were selected. A total of 5000 controls were randomly sampled from the person-time of study cohort. Current users were defined if a prescription ended within 15 days of the index date, and nonusers if there was no prescription before the index date.
RESULTS: One hundred and twenty-eight patients were considered as valid cases, being the crude incidence rate of 2.4 (95% confidence interval: 2.0, 2.8) per 100 000 person-years. The strongest associations were found with chlorpromazine (adjusted odds ratio (AOR); 95% CI = 416; 45, 3840), amoxicillin/clavulanic acid (AOR = 94.8; 27.8, 323), flucloxacillin (AOR = 17.7; 4.4, 71.0), macrolides (AOR = 6.9; 2.3, 21.0), tetracyclines (AOR = 6.2; 2.4, 15.8); metoclopramide (AOR = 6.2; 1.8, 21.3); chlorpheniramine (AOR = 9.6; 1.9, 49.7); betahistine (AOR = 15.3; 2.9, 80.7); sulphasalazine (AOR = 25.5; 6.0, 109); azathioprine (AOR = 10.5; 1.4, 76.4), diclofenac (AOR = 4.1; 1.9, 8.8) and antiepileptics (AOR = 5.1; 1.9, 13.7). A dose-effect was apparent for diclofenac, amoxicillin/clavulanic acid and flucloxacillin. The combination of two or more hepatotoxic drugs increased the risk by a factor of 6. The highest crude incidence rates were found for chlorpromazine, azathioprine, and sulfasalazine (about 1 per 1000 users).
CONCLUSIONS: Idiopathic, acute and clinically relevant liver injury, which has the use of drugs as the most probable aetiology, is a rare event in the general population. The relative risks of 40 drugs/therapeutic classes are provided, along with the crude incidence rates for 15 of them where a statistical association was found.

Entities:  

Mesh:

Year:  2004        PMID: 15206996      PMCID: PMC1884531          DOI: 10.1111/j.1365-2125.2004.02133.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  18 in total

Review 1.  Criteria of drug-induced liver disorders. Report of an international consensus meeting.

Authors:  C Bénichou
Journal:  J Hepatol       Date:  1990-09       Impact factor: 25.083

2.  Use of the UK General Practice Research Database for pharmacoepidemiology.

Authors:  L A García Rodríguez; S Pérez Gutthann
Journal:  Br J Clin Pharmacol       Date:  1998-05       Impact factor: 4.335

3.  Hepatic injury and pancreatitis during treatment with serotonin reuptake inhibitors: data from the World Health Organization (WHO) database of adverse drug reactions.

Authors:  Olav Spigset; Staffan Hägg; Andrew Bate
Journal:  Int Clin Psychopharmacol       Date:  2003-05       Impact factor: 1.659

4.  Co-amoxiclav jaundice: clinical and histological features and HLA class II association.

Authors:  J O'Donohue; K A Oien; P Donaldson; J Underhill; M Clare; R N MacSween; P R Mills
Journal:  Gut       Date:  2000-11       Impact factor: 23.059

5.  Cohort study of hepatotoxicity associated with nimesulide and other non-steroidal anti-inflammatory drugs.

Authors:  Giuseppe Traversa; Clara Bianchi; Roberto Da Cas; Iosief Abraha; Francesca Menniti-Ippolito; Mauro Venegoni
Journal:  BMJ       Date:  2003-07-05

6.  Incidence of drug-induced hepatic injuries: a French population-based study.

Authors:  Catherine Sgro; François Clinard; Kader Ouazir; Henry Chanay; Christian Allard; Christian Guilleminet; Claude Lenoir; Alain Lemoine; Patrick Hillon
Journal:  Hepatology       Date:  2002-08       Impact factor: 17.425

7.  Association between body mass index and liver disorders: an epidemiological study.

Authors:  Christoph R Meier; Stephan Krähenbühl; Raymond G Schlienger; Hershel Jick
Journal:  J Hepatol       Date:  2002-12       Impact factor: 25.083

8.  Cholestatic hepatitis associated with flucloxacillin.

Authors:  L E Derby; H Jick; D A Henry; A D Dean
Journal:  Med J Aust       Date:  1993-05-03       Impact factor: 7.738

9.  Drug-induced hepatic injury: an analysis of 1100 cases reported to the Danish Committee on Adverse Drug Reactions between 1978 and 1987.

Authors:  H Friis; P B Andreasen
Journal:  J Intern Med       Date:  1992-08       Impact factor: 8.989

10.  Prospective surveillance of acute serious liver disease unrelated to infectious, obstructive, or metabolic diseases: epidemiological and clinical features, and exposure to drugs.

Authors:  Luisa Ibáñez; Eulàlia Pérez; Xavier Vidal; Joan Ramon Laporte
Journal:  J Hepatol       Date:  2002-11       Impact factor: 25.083

View more
  91 in total

1.  Preempting and preventing drug-induced liver injury.

Authors:  Guruprasad P Aithal; Ann K Daly
Journal:  Nat Genet       Date:  2010-08       Impact factor: 38.330

2.  Ascertainment of acute liver injury in two European primary care databases.

Authors:  A Ruigómez; R Brauer; L A García Rodríguez; C Huerta; G Requena; M Gil; Francisco de Abajo; G Downey; A Bate; M Feudjo Tepie; M de Groot; R Schlienger; R Reynolds; O Klungel
Journal:  Eur J Clin Pharmacol       Date:  2014-07-29       Impact factor: 2.953

Review 3.  Validity of diagnostic coding within the General Practice Research Database: a systematic review.

Authors:  Nada F Khan; Sian E Harrison; Peter W Rose
Journal:  Br J Gen Pract       Date:  2010-03       Impact factor: 5.386

Review 4.  Pharmacogenomics of acetylsalicylic acid and other nonsteroidal anti-inflammatory agents: clinical implications.

Authors:  Eugenia Yiannakopoulou
Journal:  Eur J Clin Pharmacol       Date:  2013-02-24       Impact factor: 2.953

5.  Development of HepG2-derived cells expressing cytochrome P450s for assessing metabolism-associated drug-induced liver toxicity.

Authors:  Jiekun Xuan; Si Chen; Baitang Ning; William H Tolleson; Lei Guo
Journal:  Chem Biol Interact       Date:  2015-10-22       Impact factor: 5.192

6.  Susceptibility to amoxicillin-clavulanate-induced liver injury is influenced by multiple HLA class I and II alleles.

Authors:  M Isabel Lucena; Mariam Molokhia; Yufeng Shen; Thomas J Urban; Guruprasad P Aithal; Raúl J Andrade; Christopher P Day; Francisco Ruiz-Cabello; Peter T Donaldson; Camilla Stephens; Munir Pirmohamed; Manuel Romero-Gomez; Jose Maria Navarro; Robert J Fontana; Michael Miller; Max Groome; Emmanuelle Bondon-Guitton; Anita Conforti; Bruno H C Stricker; Alfonso Carvajal; Luisa Ibanez; Qun-Ying Yue; Michel Eichelbaum; Aris Floratos; Itsik Pe'er; Mark J Daly; David B Goldstein; John F Dillon; Matthew R Nelson; Paul B Watkins; Ann K Daly
Journal:  Gastroenterology       Date:  2011-04-12       Impact factor: 22.682

7.  Drug-induced liver injury caused by intravenously administered medications: the Drug-induced Liver Injury Network experience.

Authors:  Marwan Ghabril; Robert Fontana; Don Rockey; Gu Jiezhun; Naga Chalasani
Journal:  J Clin Gastroenterol       Date:  2013-07       Impact factor: 3.062

8.  Population pharmacokinetics at two dose levels and pharmacodynamic profiling of flucloxacillin.

Authors:  Cornelia B Landersdorfer; Carl M J Kirkpatrick; Martina Kinzig-Schippers; Jürgen B Bulitta; Ulrike Holzgrabe; George L Drusano; Fritz Sörgel
Journal:  Antimicrob Agents Chemother       Date:  2007-06-18       Impact factor: 5.191

9.  Assessment of case definitions for identifying acute liver injury in large observational databases.

Authors:  Aaron J Katz; Patrick B Ryan; Judith A Racoosin; Paul E Stang
Journal:  Drug Saf       Date:  2013-08       Impact factor: 5.606

10.  Cytochrome P450 2C8 pharmacogenetics: a review of clinical studies.

Authors:  Elizabeth B Daily; Christina L Aquilante
Journal:  Pharmacogenomics       Date:  2009-09       Impact factor: 2.533

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.